AIDP Inc. releases science white paper on PreticX
New prebiotic ingredient offers improved healthy microflora and better digestive health
AIDP Inc., City of Industry, Calif., today released a “Science White Paper” based on the peer-reviewed and published science, including a 2014 randomized, controlled trial from the University of California, Los Angeles (UCLA), behind the mechanism of action, safety and efficacy of its new prebiotic ingredient, PreticX.
PreticX is a non-genetically modified organism prebiotic that has a generally recognized safe status, and has been shown in clinical studies to significantly increase the proliferation of good gut bacteria. Bifidobacterium, at a very low dosage, provides a significant better tolerance profile as compared to other prebiotics, the company says.
“Advancing scientific research continues to demonstrate that balanced gut microbiota is essential for digestive function and that an unhealthy microbiota balance in the gut is a precursor to serious digestive issues and immune dysfunctions. The use of both prebiotic and probiotic products will continue to grow as consumers begin to understand that their digestive and immune function will decline gradually with age,” Jennifer Gu, Ph.D., AIDP’s vice president of research and development, said in a statement.
“PreTicX, a new prebiotic XOS, provides unique benefits including a low effective dosage, superior gastrointestinal safety, acid and temperature stability, and excellent taste profile,” Gu continued. “It has strong clinical data on its ability to increase healthy microflora as well as reduce biomarkers of certain health conditions. PreticX presents a compelling option in both foods and supplements to effectively target and promote gastrointestinal health.”
The 2014 UCLA study determined the tolerance and effects of prebiotic xylooligosaccaraides (XOS) to gut microbiota and whether these changes could be achieved without side effects. The study showed that bifidobacterium counts increased in both PreticX groups compared to the placebo subjects, the company says. Additionally, when the prebiotics were compared, researchers found that bifidobacterium favored XOS and confirmed findings from other human and animal studies, suggesting that XOS is an effective prebiotic that can change microbiota levels with a lower dose. PreticX, a non-GMO project verified oligosaccharides, has been clinically shown to increase bifidobacteria in the colon and aid in healthy digestion, with a low effective dose, making it a versatile and stable ingredient for use in both supplements and food products, it says.
The White Paper notes:
• PreticX increases bifidobacterial as low as 1.4mg per day.
• PreticX supplementation selectively activates beneficial but not harmful bacteria.
• XOS significantly decreased serum triglyceride, cholesterol and glucose concentrations.
• PreticX supplementation changes the microenvironment associated with obesity.
• PreticX induced a favorable change in gut microbiota and biomarkers in Diabetic and pre-DM individuals..
Advancing scientific research continues to demonstrate that balanced gut microbiota is essential for digestive function, and that an unhealthy balance in the gut is a precursor to digestive issues, immune dysfunction and the development of disease, the company says. Consumers are beginning to better understand these concepts, and as they realize that their digestive and immune function will decline gradually with age, the use of both prebiotic and probiotic products will see continued momentum.